Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Cambridge British Heart Foundation |
---|---|
Information provided by: | University of Cambridge |
ClinicalTrials.gov Identifier: | NCT00429897 |
The principle objective of the study is to determine whether low-renin (i.e. salt sensitive) hypertension at a young age is caused by the kidneys hanging onto too much salt as a result of an over active salt pump in the kidney.
The kidneys have four different salt pumps, and each is blocked by a different type of diuretic (salt losing tablet)If one out of the four is overactive, we would expect patients to respond much better to one diuretic than to the alternatives - rather than responding equally well to all available types of diuretic.
Condition | Intervention |
---|---|
Low-Renin Hypertension |
Drug: Bendroflumethiazide 2.5mg - 5mg Drug: Amiloride 20-40mg Drug: Spironolactone 50-100mg Drug: Frusemide 20-40mg Drug: Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study |
Official Title: | Double Blind Crossover Comparison od Diuretics in Young Patients With Low Renin Hypertension |
Estimated Enrollment: | 30 |
Study Start Date: | August 2006 |
Estimated Study Completion Date: | July 2007 |
Studies suggest that patients with low renin hypertension respond better to diuretics than other hypertensive drug groups. The aim of the study is to rotate patients through the four main diuretic groups and see if it is possible to identify the most effective diuretic for this group, as measured by a >=10mgHg decrease in Systolic blood pressure in one specific group a compared to the others.
As most caucasians with Low renin hypertension are older (>55), presentation with this type of hypertension at a younger age suggests the presence of substantial genetic variation in order to cause the atypical presentation. It is hoped that by identifying the best diuretic for these patients we will also be able to identify:
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Morris J Brown, Professor | 01223 336743 | mjb14@medschl.cam.ac.uk |
United Kingdom | |
University of Cambridge - Addenbrookes Hospital | Recruiting |
Cambridge, United Kingdom, CB2 2QQ | |
Contact: Morris J Brown, Proffessor 01223 336743 mjb14@medschl.cam.uk | |
Sub-Investigator: Sue Hood, RGN - sister | |
Sub-Investigator: Diane Picton, RGN- sister | |
Sub-Investigator: Tim Burton, Phd, MRCP |
Principal Investigator: | Morris J Brown, Proffessor | Cambridge University |
Study ID Numbers: | 1.0 |
Study First Received: | January 31, 2007 |
Last Updated: | January 31, 2007 |
ClinicalTrials.gov Identifier: | NCT00429897 History of Changes |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency; United Kingdom: Research Ethics Committee |
Hypertension Low Renin |
Hormone Antagonists Diuretics Sodium Chloride Symporter Inhibitors Hormones, Hormone Substitutes, and Hormone Antagonists Vascular Diseases Amiloride Bendroflumethiazide |
Cardiovascular Agents Antihypertensive Agents Furosemide Hormones Spironolactone Aldosterone Antagonists Hypertension |
Molecular Mechanisms of Pharmacological Action Hormone Antagonists Sodium Chloride Symporter Inhibitors Physiological Effects of Drugs Diuretics Hormones, Hormone Substitutes, and Hormone Antagonists Vascular Diseases Amiloride Bendroflumethiazide Cardiovascular Agents |
Antihypertensive Agents Pharmacologic Actions Spironolactone Membrane Transport Modulators Aldosterone Antagonists Natriuretic Agents Therapeutic Uses Cardiovascular Diseases Sodium Channel Blockers Hypertension |